Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients

Leukemia Research

Volumn 34, Issue 11, 2010, Pages 1430-1436

  Park, Sophie ^a   Kelaidi, Charikleia ^b   Sapena, Rosa ^a   Vassilieff, Dominique ^a   Beyne Rauzy, Odile ^c   Coiteux, Valérie ^d   Vey, Norbert ^e   Ravoet, Christophe ^f   Cheze, Stéphane ^g   Rose, Christian ^d   Legros, Laurence ^h   Stamatoullas, Aspasia ⁱ   Escoffre Barbe, Martine ^j   Guerci, Agnès ^k   Chaury, Marie Pierre ^l   Fenaux, Pierre ^b   Dreyfus, François ^a  

^a APHP ^*  (France)

^b AVICENNE HOSPITAL   (France)

^c CHU PURPAN   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f Hospital de Jolimont   (Belgium)

^g CHU Clemenceau   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ CENTRE HENRI BECQUEREL   (France)

^j PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF NANCY   (France)

^l LIMOGES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

EPO; ESA; Myelodysplastic syndrome; Transfusion

Indexed keywords

ERYTHROPOIETIN; FERRITIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; RECOMBINANT PROTEIN;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; EARLY INTERVENTION; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEEDS ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; THERAPY DELAY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; EPOETIN ALFA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME; RECOMBINANT PROTEINS;

EID: 77957016201     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.05.030     Document Type: Article

References (24)

1. Jabbour E., Kantarjian H.M., Koller C., Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 2008, 112:1089-1095.
2. Culleton B.F., Manns B.J., Zhang J., Tonelli M., Klarenbach S., Hemmelgarn B.R. Impact of anemia on hospitalization and mortality in older adults. Blood 2006, 107:3841-3846.
3. Clavio M., Nobili F., Balleari E., et al. Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. Eur J Haematol 2004, 72:113-120.
4. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
5. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120:1037-1046.
6. Park S., Grabar S., Kelaidi C., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008, 111:574-582.
7. Itzykson R., Ayari S., Vassilief D., et al. Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases. Leukemia 2009, 23:673-678.
8. Casadevall N., Durieux P., Dubois S., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004, 104:321-327.
9. Kelaidi C., Park S., Brechignac S., et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res 2008, 32:1049-1053.
10. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
11. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998, 103:1070-1074.
12. Stasi R., Brunetti M., Bussa S., et al. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 1997, 3:733-739.
13. Anargyrou K., Vaiopoulos G., Terpos E., et al. Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia. Haematologia (Budap) 2002, 32:169-173.
14. Giraldo P., Nomdedeu B., Loscertales J., et al. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 2006, 107:2807-2816.
15. Spiriti M.A., Latagliata R., Niscola P., et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 2005, 84:167-176.
16. Gabrilove J., Paquette R., Lyons R.M., et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008, 142:379-393.
17. Terpos E., Mougiou A., Kouraklis A., et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002, 118:174-180.
18. Hellstrom-Lindberg E., Negrin R., Stein R., et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997, 99:344-351.
19. Jadersten M., Malcovati L., Dybedal I., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26:3607-3613.
20. Koury M.J., Bondurant M.C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990, 248:378-381.
21. Claessens Y.E., Park S., Dubart-Kupperschmitt A., et al. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood 2005, 105:4035-4042.
22. Zermati Y., Garrido C., Amsellem S., et al. Caspase activation is required for terminal erythroid differentiation. J Exp Med 2001, 193:247-254.
23. Aoki I., Higashi K., Homori M., Chikazawa H., Ishikawa K. Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in aplastic anemia and myelodysplastic syndrome. Am J Hematol 1990, 35:6-12.
24. Rigolin G.M., Porta M.D., Ciccone M., et al. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. Br J Haematol 2004, 126:501-507.